Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2043Neoplasms 1458Carcinoma, Non-Small-Cell Lung 1360Prostatic Neoplasms 1104Multiple Myeloma 870Leukemia, Myeloid, Acute 767Colorectal Neoplasms 710Neoplasm Metastasis 702Lung Neoplasms 696Melanoma 683Lymphoma 665Leukemia 595Lymphoma, Non-Hodgkin 592Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 530Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 483Recurrence 474Myelodysplastic Syndromes 424Lymphoma, Follicular 418Carcinoma, Renal Cell 410Head and Neck Neoplasms 407Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 374Hodgkin Disease 354Carcinoma, Hepatocellular 332Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

Melatonin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Autism Spectrum Disorder × Clear all
NCT01906866 2024-04-23

Efficacy and Safety of CircadinĀ® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

Neurim Pharmaceuticals Ltd.

Phase 3 Completed
125 enrolled 22 charts

Autism Spectrum Disorder, Sleep Wake Disorders, Tuberous Sclerosis, Angelman Syndrome, Parasomnias, Smith-Magenis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔